Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers
Latest Information Update: 07 Oct 2022
At a glance
- Drugs VXA-A1-1 (Primary) ; Influenza virus vaccine
- Indications Influenza A virus H1N1 subtype
- Focus Therapeutic Use
- Acronyms Challenge
- Sponsors Vaxart
- 18 Nov 2021 Results presented in a Vaxart media release.
- 22 Jan 2020 According to a Vaxart media release, results were published in the Lancet Infectious Diseases, January 21, 2020 and currently available at doi.org/10.1016/S1473-3099(19)30584-5.
- 22 Jan 2020 Results presented in a Vaxart Media Release.